Pharmaceutical Solutions
End-to-end drug development that supports quality, safety, scalability, and compliance
End-to-End Drug Development
MRIGlobal provides end-to-end pharmaceutical development expertise that is critical for ensuring the quality, scalability, and regulatory compliance of therapeutics throughout the drug development lifecycle. From early research to clinical trial support, we serve as a partner that can help accelerate development timelines, reduce technical and supply chain risk, support product quality, and streamline complex development, storage, and logistics operations.
Our Integrated Pharmaceutical Solutions
-
Clinical Trial Materials Management
Integrated manufacturing, storage, packaging, labeling, and distribution supporting successful clinical trials -
Reference Standard Management
Qualification and management to ensure reference standards are always maintained in a qualified state -
Foreign-Trade Zone Services
Flexible importation, storage, testing, and distribution solutions supporting global pharmaceutical development -
GMP Manufacturing Support
Development, manufacturing, testing, and quality services supporting successful clinical programs -
Discovery to Clinical Supply
Integrated drug development support from early research through clinical trial readiness
"Members of the team are willing to discuss the project at length and feel like an extension of our team."
Latest from the blog
-
MRIGlobal’s SCALE Center is a major part of the $34 Million Tech Hubs Award that the EDA intends to provide to the KC BioHub Consortium
Kansas City’s newest chapter in a long tradition of world-changing science: bringing life-saving medicines closer to the patients who need them.
Biologics Pharmaceutical -
Safeguarding a Clinical Trial Amid Regulatory and Logistical Constraints
Expertise enabled client to proceed without delay
Clinical Trial Materials Management Foreign-Trade Zone Warehouse & Distribution -
Trouble with Tariffs?
On Thursday, Sept. 25, President Trump announced 100% tariffs on some imported brand-name drugs starting October 1, unless manufacturers build U.S. plants to boost domestic production. As this new tariff policy is enacted, it may have an adverse impact on pharmaceutical companies by increasing the cost of importing raw materials, drug substances and drug products, […]
Clinical Trial Materials Management Foreign-Trade Zone Warehouse & Distribution
